Early Win for PTSD Drug; FDA OKs AI Sleep Diagnostic; Extreme Social Isolation Tool

Derick Alison
Derick Alison
2 Min Read

ALTO-100, an investigational drug that works to restore plasticity in the brain, yielded a larger reduction in CAPS-5 scores in patients with biomarker-defined post-traumatic stress disorder (PTSD) versus those without the biomarker profile after 4 weeks in a phase IIa study, said Alto Neuroscience.

For patients with psychosis, both virtual reality cognitive treatment and virtual reality mental relaxation were associated with improvements in persecutory delusions, though the researchers noted that they cannot be certain the treatments accounted for the change. (The Lancet Psychiatry)

The artificial intelligence-based sleep disorder diagnostic algorithm Somnum AI was cleared by the FDA, maker HoneyNaps announced.

Hospital visits for drug- and alcohol-related disorders rose with increasing temperatures in New York, a study in Communications Medicine found.

Researchers developed a new tool to assess people for an extreme form of social isolation called hikikomori. (World Psychiatry)

People without a history of a psychotic disorder had a significantly higher risk for developing a schizophrenia spectrum disorder after an emergency department visit for substance use. (JAMA Psychiatry)

BMC Psychiatry laid out its plan to provide a preliminary summary of how the new ICD-11 classification has changed the diagnosis, treatment, and research of mental illnesses for better or worse.

Training to suppress unwanted thoughts may have possible mental health benefits. (Science Advances)

A Swedish study found no evidence to suggest that children treated with antidepressants for unipolar depression had a higher risk of treatment-emergent mania/hypomania after 12 weeks. (JAMA Psychiatry)

The family of a man who died in a Virginia psychiatric hospital after being handcuffed and pinned to the floor for 11 minutes reached an $8.5 million settlement. (AP)

U.S. surgeon Carrie Cunningham, MD, spoke out about suicide in her specialty. (The Guardian)

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.

Source link

Leave a comment
adbanner